620 related articles for article (PubMed ID: 16028101)
1. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
2. Kinetic study on the reactions of platinum drugs with glutathione.
Hagrman D; Goodisman J; Souid AK
J Pharmacol Exp Ther; 2004 Feb; 308(2):658-66. PubMed ID: 14610218
[TBL] [Abstract][Full Text] [Related]
3. Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group.
Mandal R; Kalke R; Li XF
Chem Res Toxicol; 2004 Oct; 17(10):1391-7. PubMed ID: 15487901
[TBL] [Abstract][Full Text] [Related]
4. Effects of cisplatin on mitochondrial function in Jurkat cells.
Tacka KA; Dabrowiak JC; Goodisman J; Penefsky HS; Souid AK
Chem Res Toxicol; 2004 Aug; 17(8):1102-11. PubMed ID: 15310242
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
6. Experimental and theoretical studies on the pharmacodynamics of cisplatin in jurkat cells.
Tacka KA; Szalda D; Souid AK; Goodisman J; Dabrowiak JC
Chem Res Toxicol; 2004 Nov; 17(11):1434-44. PubMed ID: 15540941
[TBL] [Abstract][Full Text] [Related]
7. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
8. Caspase activation by anticancer drugs: the caspase storm.
Tao Z; Goodisman J; Penefsky HS; Souid AK
Mol Pharm; 2007; 4(4):583-95. PubMed ID: 17439154
[TBL] [Abstract][Full Text] [Related]
9. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond E; Faivre S; Woynarowski JM; Chaney SG
Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
[TBL] [Abstract][Full Text] [Related]
11. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
12. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.
Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G
Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093
[TBL] [Abstract][Full Text] [Related]
13. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
15. Effect of hyperthermia on the action of cis-diamminedichloroplatinum(II), rhodamine 123(2) [tetrachloroplatinum(II)], rhodamine 123, and potassium tetrachloroplatinate in vitro and in vivo.
Herman TS; Teicher BA; Chan V; Collins LS; Kaufmann ME; Loh C
Cancer Res; 1988 May; 48(9):2335-41. PubMed ID: 3356001
[TBL] [Abstract][Full Text] [Related]
16. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells.
Luo FR; Wyrick SD; Chaney SG
Oncol Res; 1998; 10(11-12):595-603. PubMed ID: 10367941
[TBL] [Abstract][Full Text] [Related]
18. Role of carbonate in the cytotoxicity of carboplatin.
Di Pasqua AJ; Goodisman J; Kerwood DJ; Toms BB; Dubowy RL; Dabrowiak JC
Chem Res Toxicol; 2007 Jun; 20(6):896-904. PubMed ID: 17497898
[TBL] [Abstract][Full Text] [Related]
19. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
Holzer AK; Manorek GH; Howell SB
Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145
[TBL] [Abstract][Full Text] [Related]
20. New platinum(II) complexes containing both an O,O'-chelated acetylacetonate ligand and a sulfur ligand in the platinum coordination sphere induce apoptosis in HeLa cervical carcinoma cells.
Muscella A; Calabriso N; De Pascali SA; Urso L; Ciccarese A; Fanizzi FP; Migoni D; Marsigliante S
Biochem Pharmacol; 2007 Jun; 74(1):28-40. PubMed ID: 17481588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
